The biosimulation market is expected to reach USD 2.88 billion by 2022 from USD 1.38 billion in
2017, at a CAGR of 15.9%. Factors such as the increase in R&D investments
in the pharmaceutical and biotechnology industries, growing adoption of biosimulation
software by regulatory bodies, technologically advanced QSP systems, need to
curtail drug discovery and development costs, and growth in the biologics and
biosimilars markets are driving the growth of this market.
Download FREE Brochure @
Product launches
& upgradations accounted for the largest share of the overall growth
strategies followed by key players between 2014 and 2017. Some of the companies that adopted this strategy include Certara, Simulation Plus, Schrödinger, ACD/Labs, and
Chemical Computing Group.
The biosimulation
market is highly competitive with several big
and small players. Prominent players in this market include Certara (US),
Simulations Plus (US), Dassault Systèmes (France), Schrödinger (US), ACD/Labs
(Canada), Chemical Computing Group (Canada), Physiomics (UK), Evidera (US), In
silico biosciences (US), INOSIM Software (Germany), Insilico Biotechnology (Germany),
LeadInvent Technologies (India), Rosa (US), Nuventra Pharma (US), and Genedata
(Switzerland).
Certara is one
of the leading players in the biosimulation market. This leading position of
the company can be attributed to its strong brand recognition and extensive
product portfolio in the market. The company has a vast presence in North
America, Europe, Asia, and Australia. In order to maintain its leading position
in the biosimulation market the company focuses on inorganic and organic growth
strategies like product launches and upgradations, expansions, acquisitions,
and partnerships. For instance, in September 2016, the company acquired d3
Medicine (Australia) to enhance the company’s expertise in the field of
modeling and simulation modeling, simulation, and regulatory science
powerhouse. Likewise, in October 2017, the company launched Phoenix 8.0 PK/PD Modeling
and Simulation software.
Simulation Plus
is the second leading player in the global biosimulation market. The company
has a vast presence in North America, South America, Europe, and Asia. In order
to maintain its leading position in the biosimulation market, the company
focuses on research and development activities and product launches. The
company invested USD 1.45 million, USD 1.33 million, and USD 0.95 million in
R&D activities in 2016, 2015, and 2014, respectively. With its focus on
R&D, the company launched version 2.0 of the Membrane Plus simulation
software in August 2017. The company‘s efforts towards enhancing its focus on
R&D and product offerings will help it to maintain its leading position in
the market. The company also focuses on acquisitions and agreements as its
growth strategies to expand its business in the global biosimulation market. In
June 2017, the company acquired DILIsym Services, Inc. (US), to expand its
product portfolio in the field of simulation software and consulting services
of drug-induced liver injury.
No comments:
Post a Comment